Location of nonmelanoma skin cancers in patients after kidney transplantation

Sułowicz, Joanna; Wojas‐Pelc, Anna; Ignacak, Ewa; Janda, Katarzyna; Bȩtkowska-Prokop, Alina; Kuźniewski, Marek; Sułowicz, Władysław

doi:10.20452/pamw.2249

Cited by 3 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The time from transplantation to the first tumor occurrence of 5 years in our study is consistent with previous results ( 9 , 14 , 16 ). However, most recent studies indicate that this period was shortening and was as short as 3.75 years ( 13 , 24 ).…”

Section: Discussionsupporting

confidence: 93%

“…Although most clinical studies in RTRs pointed to a higher incidence of cSCC than of BCC ( 10 , 15 - 18 ), some studies showed a higher incidence of BCC ( 5 , 13 , 19 ). The incidence of cSCC was higher in studies from Mexico, Brazil, Australia, and some European countries ( 6 , 8 , 10 , 14 , 16 - 18 ), while BCC was more frequent in the Mediterranean part of Europe ( 5 , 9 , 13 , 19 ). Higher BCC prevalence in our RTRs might also be explained by a high-level screening of patients before and after transplantation in our Center, whereby precancerous lesions (cSCC precursors) are diagnosed and treated early.…”

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

Risk factors for non-melanoma skin cancer development in renal transplant recipients: a 40-year retrospective study in Croatia

Bašić‐Jukić¹,

Borlinić²,

Tešanović³

et al. 2022

Croat Med J

View full text Add to dashboard Cite

Aim To determine the prevalence of non-melanoma skin cancer (NMSC) and disease-specific risk factors in renal transplant recipients (RTRs). Methods This retrospective cohort study enrolled 1232 RTRs (736 men) treated in University Hospital Center Zagreb over 40 years. The effect of sex, age at transplantation, geographic residence, dialysis vintage, and the type of immunosuppressive therapy on NMSC occurrence was investigated. Results The prevalence of NMSC was 6.81%. Overall, 60.7% of patients developed basal cell carcinoma (BCC) and 30.9% of patients developed cutaneous squamous cell carcinoma (cSCC). Only 8.3% developed both tumors. The BCC:cSCC ratio was 1.76:1. The risk for NMSC was 50% higher in men. Patients older than 50 years at transplantation were at greater risk for NMSC development. Residence in an area with higher ultraviolet exposure and dialysis vintage before transplantation did not influence NMSC development. Cyclosporine and azathioprine treatment conferred a greater risk for NMSC than tacrolimus or mycophenolate mofetil treatment. Conclusion RTRs are at high risk for NMSC development. Sex, age at transplantation, and type of immunosuppressive therapy play a role in tumor development.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 90%

Risk factors for non-melanoma skin cancer development in renal transplant recipients: a 40-year retrospective study in Croatia

Bašić‐Jukić¹,

Borlinić²,

Tešanović³

et al. 2022

Croat Med J

View full text Add to dashboard Cite

show abstract

“…57 Risk factors include age at the time of transplant, lighter skin, sun exposure history, previous NMSC diagnosis, viral infection, and genetic markers, but also the regimen used for immunosuppression. 57,60,61 While all immunosuppressive drugs can increase the risk of infection and malignancy, in one retrospective study of solid organ recipients, the rate of NMSC was higher in patients who received prednisone, cyclosporine A, and azathioprine. 62 Retrospective reviews and prospective randomized trials have shown that organ transplant recipients who switch to mammalian target-of-rapamycin inhibitors, such as sirolimus and everolimus, have a lower incidence of NMSC.…”

Section: Discussionmentioning

confidence: 99%

Treatment of New-Onset Psoriasis Post-Kidney Transplant

Kellen

Nektalova

2016

Journal of Psoriasis and Psoriatic Arthritis

View full text Add to dashboard Cite

Psoriasis is a chronic skin disorder with an autoimmune component primarily driven by overactive T cells culminating in an excessive inflammatory response. Patients have reported clearance of their psoriasis after organ transplant, due to their maintenance on immunosuppressive regimens. Flares of psoriasis post-organ transplant are more rare and often require carefully thought-out management plans. Here we report the treatment of a patient who was diagnosed with new-onset psoriasis eight months after a kidney transplant. In discussion with his nephrologist, the decision was made to increase the doses of tacrolimus and mycophenolate mofetil.

show abstract

“…Even if the most part of the literature agrees in considering sun exposure an independent risk factor for MNSC [20,21] in transplanted patients, as demonstrated by the greater prevalence of NMSC in sunexposed area. Particularly, Belloni-Fortina A et al [5] reported a higher incidence in patients with phototype II-III (73.91%)as compared to patients with phototype IV-V (26.08%) (p<0.05).…”

Section: Discussionmentioning

confidence: 99%

Neoplastic Skin Complications in Transplant Patients: Experience of an Italian Multidisciplinary Transplant Unit

F¹

2015

J Clin Exp Dermatol Res

View full text Add to dashboard Cite

Transplant patients need to be strictly followed, since the immunosuppressive therapies they usually receive can increase the risk of skin complications. This study aims to evaluate the prevalence of neoplastic skin complications in transplant patients. We analyzed 256 liver or kidney transplant patients. The follow-up mean period was 7 ± 3.5 years. The 18.36% of patients developed neoplastic complications, among these 9.37% actinic keratoses, 8.20% non-melanoma skin cancer, and 0.78% cutaneous melanoma. Among patients who developed non melanoma skin cancer, 61.90% had basal cell carcinoma, 23.81% squamous cell carcinoma, 52% Kaposi's sarcoma and 4.76%, Malherbe's epithelioma. Was also evaluated the prevalence of cutaneous neoplastic complications according the immunosuppressive regimen received by patients as follows: cyclosporine, tacrolimus, steroids, mycophenolate mofetil or everolimus, in single, double or triple therapy. This study demonstrated the increased risk of skin cancer in transplant patients during the first 7 years of follow-up and made the dermatologists aware about the need of a regularcutaneous follow up for this subset of patients.

show abstract

Location of nonmelanoma skin cancers in patients after kidney transplantation

Cited by 3 publications

References 32 publications

Risk factors for non-melanoma skin cancer development in renal transplant recipients: a 40-year retrospective study in Croatia

Risk factors for non-melanoma skin cancer development in renal transplant recipients: a 40-year retrospective study in Croatia

Treatment of New-Onset Psoriasis Post-Kidney Transplant

Neoplastic Skin Complications in Transplant Patients: Experience of an Italian Multidisciplinary Transplant Unit

Contact Info

Product

Resources

About